HER2 vaccine study for high-risk breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have HER2-positive breast cancer that was high-risk, such as leftover cancer after chemo and HER2 therapy, or was stage 3 or inflammatory at diagnosis.
- You have finished at least 6 months of HER2-targeted therapy (like trastuzumab) and your last dose was within the last 6 months.
- You are in generally good health, able to perform daily activities, and have adequate heart, kidney, liver, and blood cell function.
- You are not pregnant and agree to use effective birth control during and for 6 months after treatment.
- You do not have other active cancers, serious autoimmune diseases, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
This trial tests a vaccine (GLSI-100) that may help prevent the return of HER2-positive breast cancer. It is given to patients who still had cancer cells after initial treatment with trastuzumab, or who had stage III disease and achieved a complete response.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This Phase 2 study tests an individualized vaccine made from your tumor information to help your immune system fight hormone-positive breast cancer. You may be able to participate if you meet specific hormone-receptor, health, and treatment-timing requirements.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.